Research programme: Pseudomonas aeruginosa vaccines - IMV/YCU
Latest Information Update: 17 May 2018
At a glance
- Originator ImmunoVaccine Technologies; Yokohama City University
- Developer IMV; Yokohama City University
- Class Pseudomonas vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 03 May 2018 Immunovaccine is now called IMV
- 16 Jul 2016 No recent reports of development identified for research development in Pseudomonal-infections(Prevention) in Canada
- 06 Jul 2009 Early research in Pseudomonal infections in Canada (unspecified route)